Cancer - Werewolf Therapeutics, Inc.

Cancer

Status:

Active, open to accrual

ClinicalTrials.gov:

NCT05678998

A Phase 1 (First-In-Human [FIH]), Multi-Site, Dose Escalation and Expansion Study of WTX-330 in Adult Patients with Advanced or Metastatic Solid Tumors or Lymphoma

Drug

WTX-330

Condition

Adult Patients with Advanced or Metastatic Solid Tumors or Lymphoma